Soleno Therapeutics Inc (SLNO.OQ)
18 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|49||2017||President, Chief Executive Officer, Interim Principal Financial and Accounting Officer, Director|
|67||2017||Interim Chief Financial Officer|
|55||2013||Vice President - Research and Development|
|2014||Chairman of the Board|
- BRIEF-Soleno Therapeutics Q1 Loss Per Share $0.19
- BRIEF-Soleno Therapeutics Says QTRLY Loss Per Share From Continuing Operations $0.17 - SEC Filing
- BRIEF-Soleno Therapeutics Announces Initiation Of Phase III Clinical Trial Of DCCR In Prader-Willi Syndrome
- BRIEF-Soleno Therapeutics Reports Q4 Loss Per Share $0.43
- BRIEF-Soleno Therapeutics Announces Successful End-Of-Phase II Meeting With FDA For DCCR In Prader-Willi Syndrome